What Lung‑RADS category should be assigned for multiple sub‑6 mm pulmonary nodules detected on an initial low‑dose CT lung cancer screening, and what is the recommended follow‑up?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lung-RADS Classification for Multiple Sub-6mm Nodules on Initial CT Lung Screening

Multiple pulmonary nodules all measuring less than 6 mm on an initial low-dose CT lung cancer screening should be classified as Lung-RADS Category 2, with return to routine annual screening and no additional follow-up imaging required. 1, 2

Risk Stratification

The malignancy risk for nodules smaller than 6 mm is less than 1%, which falls below the threshold that warrants routine follow-up in lung cancer screening protocols. 1, 3 This low-risk designation applies even when multiple sub-6mm nodules are present bilaterally, as multiplicity in this size range typically indicates a benign process such as healed granulomatous disease. 3

Lung-RADS Category 2 Criteria

Lung-RADS Category 2 encompasses minimal-risk findings that require no additional workup before the next routine annual screening CT. 4, 2 This category specifically includes:

  • Solid nodules measuring less than 6 mm 1, 2
  • Ground-glass nodules up to 30 mm (per Lung-RADS 2022) 5
  • Perifissural nodules less than 10 mm 5, 2
  • Long-term stable nodules 4

The presence of multiple sub-6mm nodules does not change the Lung-RADS 2 classification or management. 1, 3

Recommended Follow-Up

Return to routine annual screening in 12 months is the appropriate management for Lung-RADS Category 2 findings. 4, 2 No interval CT imaging is indicated between annual screening rounds for these low-risk nodules. 1

Exceptions Requiring Optional Follow-Up

While routine follow-up is not recommended for sub-6mm nodules, optional 12-month follow-up CT may be considered if high-risk features are present, including: 1, 3

  • Suspicious morphology: spiculated margins or irregular borders 3
  • Upper-lobe location of a non-calcified nodule 3
  • High-risk patient factors: ≥30 pack-year smoking history, age >50 years, personal or family history of lung cancer, or relevant occupational exposures 3

However, even when these features exist, the sub-6mm size maintains the <1% malignancy probability, and the decision to pursue optional follow-up should be made after considering patient preferences and comorbidities. 1

Technical Imaging Requirements

Thin-section CT with ≤1.5 mm slice thickness and multiplanar reconstructions is essential for accurate nodule characterization and measurement. 1, 3 Thick-section scans (>1.5 mm) may miss small nodules or mischaracterize their features. 3

Low-dose technique without IV contrast is the standard protocol for lung cancer screening and nodule surveillance. 1, 6 Contrast administration is not required for nodule identification, characterization, or stability assessment. 1

Documentation Requirements

Radiology reports should explicitly state the Lung-RADS Category 2 classification and recommend return to routine annual screening to prevent unnecessary downstream imaging and patient anxiety. 3, 2 Clear communication that no interval follow-up is needed helps avoid the cascade of additional testing that can occur with ambiguous reporting. 3

Common Pitfalls to Avoid

Do not upgrade to Lung-RADS Category 3 based solely on multiplicity. 1, 3 Multiple sub-6mm nodules remain Category 2 unless individual nodules meet size criteria for higher categories or demonstrate concerning morphologic features. 2

Avoid applying Fleischner Society guidelines to lung cancer screening populations, as these guidelines are designed for incidentally detected nodules in non-screening contexts and have different management thresholds. 1 Lung-RADS is specifically designed for and should be used exclusively in lung cancer screening programs. 6, 2

Do not measure nodules to the nearest millimeter without decimal precision when using Lung-RADS 2022, as the updated version requires measurement to the first decimal place for more accurate categorization. 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.